AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:  Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00. Ellen Liversidge will submit testimony…

Read More

References for THE IMPACT OF THE FDA MODERNIZATION ACT ON THE RECRUITMENT OF CHILDREN FOR RESEARCH Vera Hassner Sharav Published in ETHICAL HUMAN SCIENCES & SERVICES Summer 2003, vol. 5 pp. 83-108 Agency for Health Care Research & Quality. (1999). Treatment of attention-deficit/hyperactivity disorder: Summary, evidence Report / Technology assessment number 11. AHQR Publication No.…

Read More

18 Deaths Linked to drug – Serzone Removed from European market, not US Fri, 17 Jan 2003 Bloomberg News reported that the antidepressant, Serzone had been linked to 25 cases of liver damage and 18 deaths. On Jan 8, 2003 European authorities removed the drug from the European market. On Jan. 9, 2003, the FDA…

Read More

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 12, 2002 If Placebo Works Without Risk,Side-Effects or Cost — Why Prescribe Anti-Depressant Drugs? FYI As we reported in yesterday’s Infomail, a major governmentfunded study found that neither Zoloft nor St.…

Read More